Registration Dossier

Administrative data

Description of key information

Calcium iodate does not exhibits acute toxicity by any of the routes.

Key value for chemical safety assessment

Acute toxicity: via oral route

Link to relevant study records
Reference
Endpoint:
acute toxicity: oral
Type of information:
(Q)SAR
Adequacy of study:
key study
Reliability:
2 (reliable with restrictions)
Justification for type of information:
QSAR prediction: migrated from IUCLID 5.6
Qualifier:
according to
Guideline:
OECD Guideline 401 (Acute Oral Toxicity)
GLP compliance:
no
Test type:
standard acute method
Species:
mouse
Strain:
Swiss
Sex:
male/female
Route of administration:
oral: drinking water
Vehicle:
unchanged (no vehicle)
Doses:
no data
No. of animals per sex per dose:
no data
Control animals:
not specified
Sex:
male/female
Dose descriptor:
LD50
Effect level:
358.667 mg/kg bw
Based on:
test mat.

The prediction was based on dataset comprised from the following descriptors: LD50
Estimation method: Taking average value from the 5 nearest neighbours


("a" and "b" )

Domain logical expression index: "a"

Parametric boundary:The target chemical should have a value of log Kow which is >= -7.18

Domain logical expression index: "b"

Parametric boundary:The target chemical should have a value of log Kow which is <= -7.18

Interpretation of results:
Toxicity Category IV
Remarks:
Migrated information Criteria used for interpretation of results: EU
Conclusions:
The acute oral median lethal dose (LD50) of calcium iodate in Swiss mouse was estimated to be 358.6667 mg/kg of body weight.
Executive summary:

The acute oral median lethal dose (LD50) of calcium iodate in Swiss mouse was estimated to be 358.6667 mg/kg of body weight. This value suggest that Calcium iodate exhibits acute toxicity in the Category 4 which is relatively non toxic.

Endpoint conclusion
Endpoint conclusion:
adverse effect observed
Dose descriptor:
LD50
Value:
358.667 mg/kg bw
Quality of whole database:
The data is K2 level as the data has been obtained from QSAR model considered reliable by OECD.

Acute toxicity: via inhalation route

Link to relevant study records
Reference
Endpoint:
acute toxicity: inhalation
Data waiving:
study scientifically not necessary / other information available
Justification for data waiving:
other:
Endpoint conclusion
Endpoint conclusion:
no study available

Acute toxicity: via dermal route

Link to relevant study records
Reference
Endpoint:
acute toxicity: dermal
Type of information:
(Q)SAR
Adequacy of study:
weight of evidence
Reliability:
2 (reliable with restrictions)
Justification for type of information:
QSAR prediction: migrated from IUCLID 5.6
Qualifier:
according to
Guideline:
other:
Principles of method if other than guideline:
Data is predicted using QSAR toolbox Version 2.3
GLP compliance:
no
Test type:
fixed dose procedure
Species:
other: Human
Strain:
other: not applicable
Sex:
not specified
Type of coverage:
not specified
Vehicle:
not specified
Duration of exposure:
no data
Doses:
no data
No. of animals per sex per dose:
no data
Control animals:
not specified
Sex:
not specified
Dose descriptor:
other: "Discriminating Dose"
Effect level:
1 300 mg/kg bw
Based on:
test mat.

The prediction was based on dataset comprised from the following descriptors: "discriminating dose"
Estimation method: Taking average value from the 5 nearest neighbours


("a" and "b" )

Domain logical expression index: "a"

Parametric boundary:The target chemical should have a value of log Kow which is >= 0.0436

Domain logical expression index: "b"

Parametric boundary:The target chemical should have a value of log Kow which is <= 0.0436

Interpretation of results:
Toxicity Category IV
Remarks:
Migrated information Criteria used for interpretation of results: EU
Conclusions:
The discriminating Dose of potassium iodate in human was found to be 1300 mg/kg of body weight. Acute dermal toxicity of potassium iodate to human by dermal route indicates that this substance exhibits acute toxicity in Category 4.
Executive summary:

The discriminating Dose of potassium iodate in human was found to be 1300 mg/kg of body weight. Acute dermal toxicity of potassium iodate to human by dermal route indicates that this substance exhibits acute toxicity in Category 4.

Endpoint conclusion
Endpoint conclusion:
adverse effect observed
Dose descriptor:
discriminating dose
Value:
1 300 mg/kg bw
Quality of whole database:
The data is K2 level as the data has been obtained from QSAR model considered reliable by OECD.

Additional information

Acute toxicity: oral

Based on the various studies available with Klimish rating 2and 4 for the target substance Calcium iodate and read across substances and based on the category approach of organic functional group along with similar mechanistic approach and having structural similarities defined by QSAR toolbox. The results is summarized as follows

 

Sr.No

Endpoint

Effect values

Species

Route

Remarks

1

LD50

358.6667 mg/kg

 

mouse

Oral

Predicted data of target chemical

2

LD50

1177 mg/kg

815 mg/kg

531 mg/kg

mice

Oral intraesophageal

Data of publication for CAS NO 7758-05-6

3

LD50

505 mg/kg

mice

Oral intraesophageal

Data of publication for CAS NO 7681-55-2

4

LD

700 mg/kg

Rabbit

Oral

Data of publication for CAS NO 7681-11-0

5

LD50

200-250 mg/kg

Dog

Oral capsule

Data of publication for CAS NO 7758-05-6

6

other toxicity

260 mg/kg

Human

Oral

Data of publication for CAS NO 7681-11-0

 

By applying weight of evidence approach to the studies summarized in the above table it can be observed that the LD50 value was found to be in the range of 200 to 1177 mg/kg.Also there is evidence of toxicity effect to Human of calcium iodate. Thus according to CLP criteria it is concluded that the substance Calcium iodate exhibits acute toxicity in the Category 4.

 

Acute toxicity: inhalation

This end point was considered for waiver since calcium iodate has negligible vapour pressure and therefore exposure via the inhalation route is will not take place, justifying this end point for waiver.

Acute toxicity: dermal

The acute dermal toxicity values for the target substance are not available. The acute dermal median lethal dose (LD50) value of read across substance is considered for this endpoint. The discriminating dose value of potassium iodate in human were considered for this end point.

The discriminating Dose of potassium iodate in human was found to be 1300 mg/kg of body weight. Acute dermal toxicity of potassium iodate to human by dermal route indicates that this substance exhibits acute toxicity in Category 4.


Justification for selection of acute toxicity – oral endpoint
The acute oral median lethal dose (LD50) of calcium iodate in Swiss mouse was estimated to be 358.6667 mg/kg of body weight. This value suggest that Calcium iodate exhibits acute toxicity in the Category 4 which is relatively non toxic.

Justification for selection of acute toxicity – inhalation endpoint
This end point was considered for waiver since calcium iodate has negligible vapour pressure and therefore exposure via the inhalation route is will not take place, justifying this end point for waiver.

Justification for selection of acute toxicity – dermal endpoint
The discriminating Dose of potassium iodate in human was found to be 1300 mg/kg of body weight. Acute dermal toxicity of potassium iodate to human by dermal route indicates that this substance exhibits acute toxicity in Category 4.

Justification for classification or non-classification

According to new CLP regulation classification criteria and based on the values of acute toxicity via oral, inhalative and dermal route it is concluded that the substance calcium iodate is classified as acutely toxic by oral, inhalation or dermal route in Toxic category 4.